Company intelligence
BOOST Pharma
Treating the untreatable
Biotechnology Research
København N, DK
18 employees
Founded 2019
3 public signals
About BOOST Pharma
BOOST Pharma is based on years of collaborative research from Karolinska Institute in Stockholm with the focus on novel cell therapy treatments for Osteogenesis Imperfecta. The research teams of associate professor Cecilia Götherström and professor Magnus Westgren have shown that that treatment with BOOST Cells greatly enhanced the quality of life for patients suffering from this otherwise extremely debilitating disease.
Verified activity
Signals from BOOST Pharma
3 published signals
Research & Knowledge
BOOST Pharma is developing BT-101, a novel, investigational, off-the-shelf CellTherapy in Phase III for children with severe OsteogenesisImperfecta (OI).
Reported by BOOST Pharma
Products & Services
BOOST Pharma unveiled a new website providing an overview of its mission to advance a potentially disease-modifying therapy for children living with severe osteogenesis imperfecta (OI), including progress with BT-101.
Reported by Hans T. Schambye
Presence & Recognition
BOOST Pharma was featured on the BioHub podcast episode hosted by Max Brennan, MSc, discussing the strategy, culture, and future of BT-101 as it advances towards late-stage clinical development.
Reported by BOOST Pharma